{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2"},{"groupId":"OG001","value":"50.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"title":"Abdominal Pain, Presurgical/Surgery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4"},{"groupId":"OG001","value":"32.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"Abdominal Pain, Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0"},{"groupId":"OG001","value":"48.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"Abdominal Pain, Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3"},{"groupId":"OG001","value":"54.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Abdominal Pain, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1"},{"groupId":"OG001","value":"57.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Abdominal Pain, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5"},{"groupId":"OG001","value":"58.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Abdominal Pain, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.7"},{"groupId":"OG001","value":"48.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Abdominal Pain, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0"},{"groupId":"OG001","value":"51.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"title":"Abdominal Pain, Completion of Treatment/Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3"},{"groupId":"OG001","value":"51.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Abdominal Pain, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3"},{"groupId":"OG001","value":"51.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Abdominal Pain, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Abdominal Pain, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6"},{"groupId":"OG001","value":"58.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Abdominal Pain, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Abdominal Pain, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Abdominal Pain, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7"},{"groupId":"OG001","value":"54.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"Bloating, Presurgical/Surgery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0"},{"groupId":"OG001","value":"59.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"title":"Bloating, Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0"},{"groupId":"OG001","value":"66.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"Bloating, Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9"},{"groupId":"OG001","value":"63.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Bloating, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5"},{"groupId":"OG001","value":"63.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Bloating, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"64.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Bloating, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3"},{"groupId":"OG001","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Bloating, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1"},{"groupId":"OG001","value":"58.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"title":"Bloating, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3"},{"groupId":"OG001","value":"53.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Bloating, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2"},{"groupId":"OG001","value":"62.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Bloating, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4"},{"groupId":"OG001","value":"63.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Bloating, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"62.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Bloating, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Bloating, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Bloating, Post-Treatment Follow Up 24 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"Clinically-meaningful improvement defined as a \\>=10-point decrease from the baseline score in patient-reported abdominal pain or bloating will be assessed using European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires Ovarian Cancer Module 28 (EORTC QLQ-OV28) Abdominal/Gastrointestinal Symptom Scale (Items 31 and 31).","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.","id":"OG000","title":"Placebo With Paclitaxel, Carboplatin and Bevacizumab"},{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG001","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Neoadjuvant Group. PRO-evaluable population is defined as patients in the ITT population with a baseline and \\>=1 post-baseline PRO assessment. The ITT population is defined as all randomized patients, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.","title":"Percentage of Participants Who Achieve a Clinically-Meaningful Improvement in Patient-Reported Abdominal Pain and Bloating - Neoadjuvant Group","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}